Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

-Rivaroxaban is factor Xa inhibitor

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sherief Abd-Elsalam
• Treatments: Rivaroxaban

Criteria

Inclusion Criteria:

• Acute PVT

Exclusion Criteria:

• Malignant PVT

• Bleeding disorders